Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts [Yahoo! Finance]
Dianthus Therapeutics, Inc. (DNTH)
Company Research
Source: Yahoo! Finance
John Davis brings direct clinical expertise as Nucleome advances from translational science to development of medicines Newly founded SAB comprises experts across dark genome genetics and drug discovery Oxford, UK, 25 April 2024 – Nucleome Therapeutics (‘Nucleome' or ‘the Company'), a biotechnology company decoding the dark matter of the human genome for translational medicine, today announces the appointment of John Davis, MD, MPH, MS as a Non-Executive Director of the Board, and the foundation of its Scientific Advisory Board (SAB), comprised of world-renowned experts across dark genome genetics and drug discovery. New Non-Executive Director of the Board, John Davis MD, MPH, MS , brings extensive and varied experience as a physician-scientist, drug developer and biotechnology executive. John serves on the Board of Sonoma Biotherapeutics and is Chair of its Science Committee. He was previously Head of Research and Development and Chief Medical Officer at Magenta Therapeutics,
Show less
Read more
Impact Snapshot
Event Time:
DNTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNTH alerts
High impacting Dianthus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DNTH
News
- Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care ConferenceGlobeNewswire
- Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Raymond James from $34.00 to $51.00. They now have an "outperform" rating on the stock.MarketBeat
- Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual MeetingGlobeNewswire
- Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
DNTH
Earnings
- 3/21/24 - Beat
DNTH
Sec Filings
- 4/11/24 - Form ARS
- 4/11/24 - Form DEFA14A
- 4/11/24 - Form DEF
- DNTH's page on the SEC website